3MNR

Crystal Structure of Benzamide SNX-1321 bound to Hsp90


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.90 Å
  • R-Value Free: 0.235 
  • R-Value Work: 0.188 
  • R-Value Observed: 0.190 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history


Literature

Application of Chemoproteomics to Drug Discovery: Identification of a Clinical Candidate Targeting Hsp90.

Fadden, P.Huang, K.H.Veal, J.M.Steed, P.M.Barabasz, A.F.Foley, B.Hu, M.Partridge, J.M.Rice, J.Scott, A.Dubois, L.G.Freed, T.A.Silinski, M.A.Barta, T.E.Hughes, P.F.Ommen, A.Ma, W.Smith, E.D.Spangenberg, A.W.Eaves, J.Hanson, G.J.Hinkley, L.Jenks, M.Lewis, M.Otto, J.Pronk, G.J.Verleysen, K.Haystead, T.A.Hall, S.E.

(2010) Chem Biol 17: 686-694

  • DOI: 10.1016/j.chembiol.2010.04.015
  • Primary Citation of Related Structures:  
    3MNR

  • PubMed Abstract: 
  • A chemoproteomics-based drug discovery strategy is presented that utilizes a highly parallel screening platform, encompassing more than 1000 targets, with a focused chemical library prior to target selection. This chemoproteomics-based process enables a data-driven selection of both the biological target and chemical hit after the screen is complete ...

    A chemoproteomics-based drug discovery strategy is presented that utilizes a highly parallel screening platform, encompassing more than 1000 targets, with a focused chemical library prior to target selection. This chemoproteomics-based process enables a data-driven selection of both the biological target and chemical hit after the screen is complete. The methodology has been exemplified for the purine binding proteome (proteins utilizing ATP, NAD, FAD). Screening of an 8000 member library yielded over 1500 unique protein-ligand interactions, which included novel hits for the oncology target Hsp90. The approach, which also provides broad target selectivity information, was used to drive the identification of a potent and orally active Hsp90 inhibitor, SNX-5422, which is currently in phase 1 clinical studies.


    Organizational Affiliation

    Serenex, Inc., 323 Foster Street, Durham, NC 27701, USA.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Heat shock protein HSP 90-alphaA [auth P]232Homo sapiensMutation(s): 0 
Gene Names: HSP90AA1HSP90AHSPC1HSPCA
UniProt & NIH Common Fund Data Resources
Find proteins for P07900 (Homo sapiens)
Explore P07900 
Go to UniProtKB:  P07900
PHAROS:  P07900
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SD1 (Subject of Investigation/LOI)
Query on SD1

Download Ideal Coordinates CCD File 
B [auth P]2-[(3,4,5-trimethoxyphenyl)amino]-4-(2,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-indol-1-yl)benzamide
C27 H31 N3 O5
ONWOLFRMYZHLEQ-UHFFFAOYSA-N
 Ligand Interaction
Binding Affinity Annotations 
IDSourceBinding Affinity
SD1 BindingDB:  3MNR IC50: 490 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.90 Å
  • R-Value Free: 0.235 
  • R-Value Work: 0.188 
  • R-Value Observed: 0.190 
  • Space Group: I 2 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 66.773α = 90
b = 90.753β = 90
c = 99.116γ = 90
Software Package:
Software NamePurpose
CrystalCleardata collection
REFMACrefinement
d*TREKdata reduction
d*TREKdata scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment  



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2010-08-11
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance